This article corrects:

  1. Influenza immunization in egg allergy: an update for the 2011–2012 season Volume 41, Issue 10, 1367–1370, Article first published online: 20 September 2011

Erlewyn-Lajeunesse M, Lucas JSA and Warner JO. Influenza immunization in egg allergy: an update for the 2011–2012 season. Clin Exp Allergy 2011; 41: 1367–70.

Two vaccines that we recommended based on their very low egg content have now been shown to contain higher amounts of egg protein, unsuitable for egg allergic individuals. Immunisers should check the Summary of Product Characteristics of any vaccine before administration.

The correct table is shown below:

Table 2. Summary of guidance for the 2011/2012 season in the UK

TypeSeasonal 2011/2012ManufacturerAge indicationsOvalbumin content (mcg/mL)Lower risk egg allergyHigher risk egg allergy
Egg freePreflucelBaxterFrom 18 yearsNo ovalbuminSingle dose in Primary careSingle dose in Primary Care
Very low egg < 0.12 mcg/mLInactivated InfluenzaSanofi Pasteur MSDFrom 6 months<0.048Single dose in Primary Care*Single dose in Hospital*
VirofluCrucell UKFrom 6 months<0.1
FluarixGlaxoSmithKlineFrom 6 months<0.1
Intanza 9 mcg**Sanofi Pasteur MSDFrom 18 to 59 years<0.048
Intanza 15 mcg**Sanofi Pasteur MSDFrom 60 years<0.048
Low egg < 1.2 mcg/mLAgrippalNovartisFrom 6 months<0.2Single dose in Hospital*Split dose in Hospital*
ImuvacAbbottFrom 6 months<0.2
 ImuvacMASTAFrom 6 months<0.2  
 InfluvacAbbottFrom 6 months<0.2  
Not appropriate > 1.2 mcg/mLCSL Inactivated InfluenzaPfizerFrom 5 years<2 mcg  
Enzira FluvirinPfizer NovartisFrom 5 years From 4 years<2 mcg <2.0Do not use in egg allergyDo not use in egg allergy

Table based upon vaccine data from Department of Health [1]. *Hospital refers to any healthcare setting used to treating anaphylaxis with a physician in attendance. A single dose is a single injection of the full vaccine dose normally 0.5 mL, a split dose refers to an initial dose of 1/10th, that is, 0.05 mL followed by the remaining 9/10th at an interval of 30 min. **Intanza is an intradermal product and the safety of this route of administration has not been established in egg allergy.